(Q44662447)

5 December 2017

title

Long-term safety and efficacy of NNRTI within the central nervous system (English)

1 reference

5 December 2017

5

Gabriele Arendt

1 reference

5 December 2017

author name string

Hans Jürgen von Giesen

1

1 reference

5 December 2017

Hubertus Köller

2

1 reference

5 December 2017

Dominique de Nocker

3

1 reference

5 December 2017

Bernhard A Haslinger

4

1 reference

5 December 2017

publication date

1 November 2003

1 reference

5 December 2017

1 reference

5 December 2017

volume

4

1 reference

5 December 2017

issue

6

1 reference

5 December 2017

page(s)

382-390

1 reference

Switch to efavirenz in a protease inhibitor-containing regimen

5 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Therapeutic effects of nonnucleoside reverse transcriptase inhibitors on the central nervous system in HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Clinical implications of CNS penetration of antiretroviral drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Motor dysfunction in HIV-infected patients without clinically detectable central-nervous deficit

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Factor structure and scoring of the SKT test battery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Manic syndrome associated with efavirenz overdose

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Efavirenz-induced psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Efavirenz-induced psychosis leading to involuntary detention

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Central nervous system adverse effects with efavirenz: case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Management of sudden psychiatric disorders related to efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

Preliminary Data of a Prospective Study on Neuropsychiatric Side Effects After Initiation of Efavirenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1310%2FVU9B-AJKE-12GM-WQHK

10.1310/VU9B-AJKE-12GM-WQHK

21 January 2018

Identifiers

DOI

1 reference

5 December 2017

1 reference